ReviewCurrent opinion in rheumatology2015
Syndesmophyte growth in ankylosing spondylitis.
Review in Current opinion in rheumatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 57 citations in OpenAlex.
- Two-year imaging outcomes from a phase 3 randomized trial of secukinumab in patients with non-radiographic axial spondyloarthritis.Arthritis research & therapy · 2023Trial
- Effects of secukinumab on bone mineral density and bone turnover biomarkers in patients with ankylosing spondylitis: 2-year data from a phase 3 study, MEASURE 1.BMC musculoskeletal disorders · 2021Trial
- Prognostic value of trabecular bone score for major osteoporotic fractures in patients with radiographic axial spondyloarthritis: a 3-year prospective cohort study.Rheumatology international · 2025Article
- A higher body mass index and increased syndesmophytes volume are associated with facet joints ankylosis on thoracic spine in patients with ankylosing spondylitis: a retrospective cohort study.BMC rheumatology · 2024Article
- Rolling on the spikes.Clinical rheumatology · 2024Article
- Article
- Biomechanics in the onset and severity of spondyloarthritis: a force to be reckoned with.RMD open · 2023Review
- Rheumatoid Diseases Involving the Cervical Spine I. History, Definition, and Diagnosis: New Trends and Technologies.Acta neurochirurgica. Supplement · 2023Review
- Associations between syndesmophytes and facet joint ankylosis in radiographic axial spondyloarthritis patients on low-dose CT over 2 years.Rheumatology (Oxford, England) · 2022Article
- Therapeutic Utility and Adverse Effects of Biologic Disease-Modifying Anti-Rheumatic Drugs in Inflammatory Arthritis.International journal of molecular sciences · 2022Review
- FunctionalCells · 2022Article
- Article
- Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease.Current osteoporosis reports · 2022Review
- Degenerative and Inflammatory Osteoproliferations in Lumbar Radiographs in Psoriatic Arthritis Patients.Journal of clinical medicine · 2022Article
- Bone Involvement in Patients with Spondyloarthropathies.Calcified tissue international · 2022Review
- Article
- Disease progression associated with low bone mass in axial spondyloarthropathy patients.Archives of osteoporosis · 2021Article
- Imaging of cervical spine involvement in inflammatory arthropathies: a review.Polish journal of radiology · 2021Review
- Article
- Loss and gain of bone in spondyloarthritis: what drives these opposing clinical features?Therapeutic advances in musculoskeletal disease · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
purpose of reviewSyndesmophytes are characteristic components of the spine disorder of ankylosing spondylitis. Understanding their growth may reveal insights to pathogenesis and potential treatment. We review recent studies on rates of development of syndesmophytes, patient characteristics associated with more rapid syndesmophyte growth, local vertebral abnormalities that precede syndesmophytes, systemic biomarkers of syndesmophytes, and studies of medications. RECENT
findingsNew syndesmophytes develop in one-third of patients over 2 years. Consistent clinical predictors are male sex, elevated serum C-reactive protein levels, and preexisting syndesmophytes. Concomitant vertebral inflammation and fat dysplasia on MRI predict future syndesmophytes at the same vertebral location, but most syndesmophytes do not have recognized antecedents. Associations with serum levels of Wingless pathway proteins are inconsistent, as are the results of observational studies of tumor necrosis factor-alpha inhibitors. SUMMARY: Although there is better understanding of the frequency of syndesmophyte development, the pathogenesis of syndesmophytes remains unclear.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.